Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir

Autor: Lenyta Oliveira Gomes, Marina Rodrigues Teixeira, Júnior André da Rosa, Alberi Adolfo Feltrin, João Paulo V. Rodrigues, Mariane D’Avila Vecchi, Jane Meire M. Carneiro, Lúcia de Araújo C. B. Noblat, Silvana Gama F. Chachá, Ana de Lourdes C. Martinelli, Leonardo Regis L. Pereira, Marysabel Pinto T. Silveira, Carine Raquel Blatt, Mareni Rocha Farias

Publikováno v: Revista do Instituto de Medicina Tropical de São Paulo, Vol 60, Iss 0 (2018)

ABSTRACT In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology

Externí odkaz: https://doaj.org/article/9d02ad81afa6421089067f67acde4271

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir

Autor: Lúcia de Araújo Costa Beisl Noblat, Júnior André da Rosa, João Paulo Vilela Rodrigues, Ana de Lourdes Candolo Martinelli, Marysabel Pinto Telis Silveira, Lenyta Oliveira Gomes, Mariane D Ávila Vecchi, Silvana Gama Florencio Chachá, Marina Rodrigues Teixeira, Leonardo Régis Leira Pereira, Mareni Rocha Farias, Carine Raquel Blatt, Alberi Adolfo Feltrin, Jane Meire M. Carneiro

Publikováno v: Revista do Instituto de Medicina Tropical de São Paulo; Vol. 60 (2018); e29
Revista do Instituto de Medicina Tropical de São Paulo; v. 60 (2018); e29
Revista do Instituto de Medicina Tropical de São Paulo
Instituto de Medicina Tropical (IMT)
instacron:IMT
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Revista do Instituto de Medicina Tropical de São Paulo, Volume: 60, Article number: e29, Published: 28 JUN 2018
Revista do Instituto de Medicina Tropical de São Paulo, Vol 60, Iss 0 (2018)

In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorpor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::483ea6dd53865c31215b795f2459d7cd
https://www.revistas.usp.br/rimtsp/article/view/148079

An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System

Autor: Giácomo Balbinotto Neto, Fabíola Bagatini, Rodrigo Fernandes Alexandre, Júnior André da Rosa, Mareni Rocha Farias, Carine Raquel Blatt, Noemia Liege Maria da Cunha Bernardo, Uwe Siebert

Publikováno v: Value in Health Regional Issues. (2):129-135

Objectives Hepatitis C therapy in Brazil is expensive due to the cost of antiviral drugs and demands on medical resources. The objective of this study was to estimate the direct costs per patient of chronic hepatitis C therapy in a Brazilian setting.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3057be8212dce579350dd2a7e8af7ed6